| Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
|---|
| Cinnarizine | hsa00030 | Pentose phosphate pathway | 9.38E-07 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | | Cinnarizine | hsa00190 | Oxidative phosphorylation | 5.12E-04 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | | Cinnarizine | hsa00220 | Arginine biosynthesis | 1.26E-03 | 3 | P15104, P05089, P49448 | GLUL, ARG1, GLUD2 | More | | | Cinnarizine | hsa00240 | Pyrimidine metabolism | 4.29E-02 | 2 | P21589, P04183 | NT5E, TK1 | More | | | Cinnarizine | hsa00250 | Alanine, aspartate and glutamate metabolism | 2.42E-02 | 1 | P15104 | GLUL | More | | | Cinnarizine | hsa00310 | Lysine degradation | 3.15E-02 | 2 | Q96KQ7, P51648 | EHMT2, ALDH3A2 | More | | | Cinnarizine | hsa00500 | Starch and sucrose metabolism | 1.34E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | | Cinnarizine | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | | | Cinnarizine | hsa00513 | Various types of N-glycan biosynthesis | 4.96E-02 | 1 | Q9NR34 | MAN1C1 | More | | | Cinnarizine | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 1.91E-02 | 1 | Q9NY97 | B3GNT2 | More | | | Cinnarizine | hsa00562 | Inositol phosphate metabolism | 2.00E-03 | 5 | Q14642, P27987, P29218, P19174, P42338 | INPP5A, ITPKB, IMPA1, PLCG1, PIK3CB | More | | | Cinnarizine | hsa00564 | Glycerophospholipid metabolism | 4.29E-02 | 2 | Q6P1A2, P23743 | MBOAT5, DGKA | More | | | Cinnarizine | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | | Cinnarizine | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | | Cinnarizine | hsa00601 | Glycosphingolipid biosynthesis - lacto and neolacto series | 3.78E-02 | 1 | Q9NY97 | B3GNT2 | More | | | Cinnarizine | hsa00630 | Glyoxylate and dicarboxylate metabolism | 1.13E-02 | 2 | P40925, P15104 | MDH1, GLUL | More | | | Cinnarizine | hsa00730 | Thiamine metabolism | 3.83E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | | Cinnarizine | hsa00760 | Nicotinate and nicotinamide metabolism | 3.52E-02 | 1 | P21589 | NT5E | More | | | Cinnarizine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | | Cinnarizine | hsa00830 | Retinol metabolism | 3.93E-02 | 3 | P00352, Q9BPW9, O75911 | ALDH1A1, DHRS9, DHRS3 | More | | | Cinnarizine | hsa00910 | Nitrogen metabolism | 2.42E-02 | 1 | P15104 | GLUL | More | | | Cinnarizine | hsa00970 | Aminoacyl-tRNA biosynthesis | 3.78E-02 | 2 | O95363, Q15046 | FARS2, KARS | More | | | Cinnarizine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | | Cinnarizine | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | | Cinnarizine | hsa00983 | Drug metabolism - other enzymes | 3.32E-02 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | | | Cinnarizine | hsa01100 | Metabolic pathways | 4.12E-02 | 6 | Q14642, P29218, Q14376, P07101, Q9UHK6, P12074 | INPP5A, IMPA1, GALE, TH, AMACR, COX6A1 | More | | | Cinnarizine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | | Cinnarizine | hsa01210 | 2-Oxocarboxylic acid metabolism | 1.91E-02 | 1 | P50213 | IDH3A | More | | | Cinnarizine | hsa01230 | Biosynthesis of amino acids | 2.05E-04 | 5 | P51854, P60891, P05089, P15104, P37837 | TKTL1, PRPS1, ARG1, GLUL, TALDO1 | More | | | Cinnarizine | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P08069 | IGF1R | More | | | Cinnarizine | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P08069 | IGF1R | More | | | Cinnarizine | hsa01523 | Antifolate resistance | 3.06E-03 | 4 | P41440, Q92820, P04818, P01375 | SLC19A1, GGH, TYMS, TNF | More | | | Cinnarizine | hsa01524 | Platinum drug resistance | 1.79E-02 | 2 | O15392, P11388 | BIRC5, TOP2A | More | | | Cinnarizine | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | | Cinnarizine | hsa03018 | RNA degradation | 5.00E-02 | 1 | Q9NQT4 | EXOSC5 | More | | | Cinnarizine | hsa03020 | RNA polymerase | 5.24E-06 | 4 | P24928, P62487, Q9GZM3, P52435 | POLR2A, POLR2G, POLR2J2, POLR2J | More | | | Cinnarizine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | | Cinnarizine | hsa03040 | Spliceosome | 9.86E-09 | 13 | O43143, O60508, P08579, P26368, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX15, CDC40, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O43143 | DHX15 | ATP-dependent RNA helicase DHX15 | -0.76 | | P07948 | LYN | Tyrosine-protein kinase Lyn | O60508 | CDC40 | Pre-mRNA-processing factor 17 | -0.814 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O60508 | CDC40 | Pre-mRNA-processing factor 17 | -0.812 | | P07948 | LYN | Tyrosine-protein kinase Lyn | P08579 | SNRPB2 | U2 small nuclear ribonucleoprotein B'' | -0.739 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08579 | SNRPB2 | U2 small nuclear ribonucleoprotein B'' | -0.822 | | P07948 | LYN | Tyrosine-protein kinase Lyn | P26368 | U2AF2 | Splicing factor U2AF 65 kDa subunit | -0.775 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P26368 | U2AF2 | Splicing factor U2AF 65 kDa subunit | -0.751 | | P07948 | LYN | Tyrosine-protein kinase Lyn | Q13595 | TRA2A | Transformer-2 protein homolog alpha | -0.742 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13595 | TRA2A | Transformer-2 protein homolog alpha | -0.74 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q07955 | SFRS1 | Serine/arginine-rich splicing factor 1 | -0.749 | | P07948 | LYN | Tyrosine-protein kinase Lyn | Q01130 | SFRS2 | Serine/arginine-rich splicing factor 2 | -0.716 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q01130 | SFRS2 | Serine/arginine-rich splicing factor 2 | -0.798 | | P07948 | LYN | Tyrosine-protein kinase Lyn | P84103 | SFRS3 | Serine/arginine-rich splicing factor 3 | -0.79 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84103 | SFRS3 | Serine/arginine-rich splicing factor 3 | -0.773 | | P07948 | LYN | Tyrosine-protein kinase Lyn | Q13243 | SFRS5 | Serine/arginine-rich splicing factor 5 | -0.781 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13243 | SFRS5 | Serine/arginine-rich splicing factor 5 | -0.822 | | P07948 | LYN | Tyrosine-protein kinase Lyn | P11142 | HSPA8 | Heat shock cognate 71 kDa protein | -0.732 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P11142 | HSPA8 | Heat shock cognate 71 kDa protein | -0.802 | | P07948 | LYN | Tyrosine-protein kinase Lyn | Q9Y2W2 | WBP11 | WW domain-binding protein 11 | -0.734 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q9Y2W2 | WBP11 | WW domain-binding protein 11 | -0.743 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O43447 | PPIH | Peptidyl-prolyl cis-trans isomerase H | -0.766 | | P07948 | LYN | Tyrosine-protein kinase Lyn | O75643 | ASCC3L1 | U5 small nuclear ribonucleoprotein 200 kDa helicase | -0.742 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O75643 | ASCC3L1 | U5 small nuclear ribonucleoprotein 200 kDa helicase | -0.745 |
| | Cinnarizine | hsa04010 | MAPK signaling pathway | 1.23E-03 | 3 | P08069, Q9H2K8, Q12933 | IGF1R, TAOK3, TRAF2 | More | | | Cinnarizine | hsa04012 | ErbB signaling pathway | 3.69E-02 | 3 | Q13191, P19174, P42338 | CBLB, PLCG1, PIK3CB | More | | | Cinnarizine | hsa04014 | Ras signaling pathway | 1.13E-02 | 9 | P42338, P20827, P49767, P08069, Q13009, Q7LDG7, P63218, P50151, P19174 | PIK3CB, EFNA1, VEGFC, IGF1R, TIAM1, RASGRP2, GNG5, GNG10, PLCG1 | More | | | Cinnarizine | hsa04015 | Rap1 signaling pathway | 5.88E-04 | 13 | P20827, P49767, P08069, Q96FS4, P11215, P25116, Q8TEU7, Q13009, Q7LDG7, P42338, P08514, P17252, P19174 | EFNA1, VEGFC, IGF1R, SIPA1, ITGAM, F2R, RAPGEF6, TIAM1, RASGRP2, PIK3CB, ITGA2B, PRKCA, PLCG1 | More | | | Cinnarizine | hsa04022 | cGMP-PKG signaling pathway | 2.55E-02 | 4 | P18848, Q8WYR1, P05141, P0DP24 | ATF4, PIK3R5, SLC25A5, CALM2 | More | | | Cinnarizine | hsa04060 | Cytokine-cytokine receptor interaction | 1.06E-04 | 16 | P14784, P27930, P14778, P26842, Q06643, Q13651, Q9HBE5, P78552, P25024, Q9UBD3, P47992, O75509, P09341, P19875, P01730, Q93038 | IL2RB, IL1R2, IL1R1, CD27, LTB, IL10RA, IL21R, IL13RA1, CXCR1, XCL2, XCL1, TNFRSF21, CXCL1, CXCL2, CD4, TNFRSF25 | More | | | Cinnarizine | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 1.32E-02 | 6 | P09341, P25024, P47992, Q9UBD3, Q13651, P14784 | CXCL1, CXCR1, XCL1, XCL2, IL10RA, IL2RB | More | | | Cinnarizine | hsa04062 | Chemokine signaling pathway | 2.28E-04 | 15 | P25024, P09341, P47992, Q9UBD3, P09769, P07948, P42338, P19174, P63218, P50151, P43250, Q08881, Q7LDG7, Q13009, Q8WYR1 | CXCR1, CXCL1, XCL1, XCL2, FGR, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, ITK, RASGRP2, TIAM1, PIK3R5 | More | | | Cinnarizine | hsa04064 | NF-kappa B signaling pathway | 2.39E-05 | 12 | O00463, P14778, P01375, P19174, Q04759, Q16548, P07948, P06239, P24522, P09341, P19875, Q06643 | TRAF5, IL1R1, TNF, PLCG1, PRKCQ, BCL2A1, LYN, LCK, GADD45A, CXCL1, CXCL2, LTB | More | | | Cinnarizine | hsa04066 | HIF-1 signaling pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | | | Cinnarizine | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | | | Cinnarizine | hsa04070 | Phosphatidylinositol signaling system | 2.65E-02 | 2 | P29218, Q14642 | IMPA1, INPP5A | More | | | Cinnarizine | hsa04071 | Sphingolipid signaling pathway | 6.68E-04 | 6 | P21453, Q9H228, P01375, Q13362, Q12933, Q02156 | S1PR1, EDG8, TNF, PPP2R5C, TRAF2, PRKCE | More | | | Cinnarizine | hsa04072 | Phospholipase D signaling pathway | 9.70E-03 | 2 | Q92529, Q14344 | SHC3, GNA13 | More | | | Cinnarizine | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | | | Cinnarizine | hsa04110 | Cell cycle | 6.80E-03 | 6 | P06493, O75293, P30304, P33981, P42773, P01106 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | | | Cinnarizine | hsa04114 | Oocyte meiosis | 2.99E-02 | 1 | P08069 | IGF1R | More | | | Cinnarizine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | | Cinnarizine | hsa04140 | Autophagy - animal | 1.29E-02 | 5 | P08069, Q9Y4H2, P42338, Q9NQL2, Q04759 | IGF1R, IRS2, PIK3CB, RRAGD, PRKCQ | More | | | Cinnarizine | hsa04142 | Lysosome | 2.64E-02 | 2 | Q99437, P25774 | ATP6V0B, CTSS | More | | | Cinnarizine | hsa04144 | Endocytosis | 1.24E-02 | 9 | Q13191, P11142, O75351, P62491, P25024, P43250, Q14161, P14784, Q9Y5X3 | CBLB, HSPA8, VPS4B, RAB11A, CXCR1, GRK6, GIT2, IL2RB, SNX5 | More | | | Cinnarizine | hsa04145 | Phagosome | 3.11E-02 | 2 | Q99437, P25774 | ATP6V0B, CTSS | More | | | Cinnarizine | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P08069 | IGF1R | More | | | Cinnarizine | hsa04151 | PI3K-Akt signaling pathway | 1.67E-03 | 18 | P62753, P42338, P43657, O43521, P27348, P20827, P49767, P08238, Q8WYR1, P63218, P50151, O15335, Q13751, P14784, P18848, O00141, Q6ZUJ8, P30281 | RPS6, PIK3CB, P2RY5, BCL2L11, YWHAQ, EFNA1, VEGFC, HSP90AB1, PIK3R5, GNG5, GNG10, CHAD, LAMB3, IL2RB, ATF4, SGK, PIK3AP1, CCND3 | More | | | Cinnarizine | hsa04152 | AMPK signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | | | Cinnarizine | hsa04210 | Apoptosis | 3.63E-02 | 3 | O75460, O43521, P18848 | ERN1, BCL2L11, ATF4 | More | | | Cinnarizine | hsa04211 | Longevity regulating pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | | | Cinnarizine | hsa04213 | Longevity regulating pathway - multiple species | 3.78E-03 | 5 | P42338, P08069, Q9Y4H2, P11142, Q13547 | PIK3CB, IGF1R, IRS2, HSPA8, HDAC1 | More | | | Cinnarizine | hsa04217 | Necroptosis | 4.76E-06 | 17 | P01375, P01568, P48023, Q13489, P42224, Q14765, P08238, P15104, P05141, P01584, P0C0S5, Q6FI13, Q99878, Q93077, Q9H444, O43633, Q08752 | TNF, IFNA21, FASLG, BIRC3, STAT1, STAT4, HSP90AB1, GLUL, SLC25A5, IL1B, H2AFZ, H2AC18; H2AC19, H2AC14, HIST1H2AC, CHMP4B, CHMP2A, PPID | More | | | Cinnarizine | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | | | Cinnarizine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | | | Cinnarizine | hsa04360 | Axon guidance | 4.04E-02 | 6 | P16333, P20827, O95631, P42338, P07332, P19174 | NCK1, EFNA1, NTN1, PIK3CB, FES, PLCG1 | More | | | Cinnarizine | hsa04370 | VEGF signaling pathway | 4.05E-02 | 2 | P19174, P42338 | PLCG1, PIK3CB | More | | | Cinnarizine | hsa04371 | Apelin signaling pathway | 1.00E-02 | 7 | P63218, P50151, Q8WYR1, Q14814, Q14344, Q13485, P84022 | GNG5, GNG10, PIK3R5, MEF2D, GNA13, SMAD4, SMAD3 | More | | | Cinnarizine | hsa04390 | Hippo signaling pathway | 4.35E-02 | 2 | P63261, O15105 | ACTG1, SMAD7 | More | | | Cinnarizine | hsa04510 | Focal adhesion | 3.48E-02 | 1 | P08069 | IGF1R | More | | | Cinnarizine | hsa04520 | Adherens junction | 8.29E-03 | 1 | P08069 | IGF1R | More | | | Cinnarizine | hsa04530 | Tight junction | 3.60E-03 | 5 | P63261, P16989, P56750, Q92974, Q14247 | ACTG1, CSDA, CLDN17, ARHGEF2, CTTN | More | | | Cinnarizine | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P08069 | IGF1R | More | | | Cinnarizine | hsa04611 | Platelet activation | 3.39E-02 | 3 | P25116, P08514, P07359 | F2R, ITGA2B, GP1BA | More | | | Cinnarizine | hsa04612 | Antigen processing and presentation | 7.49E-07 | 11 | P13765, P01730, Q14953, P26715, P26717, Q07444, Q13241, P01732, P30101, P11142, P01375 | HLA-DOB, CD4, KIR2DS5, KLRC1, KLRC2, KLRC3, KLRD1, CD8A, PDIA3, HSPA8, TNF | More | | | Cinnarizine | hsa04613 | Neutrophil extracellular trap formation | 2.18E-03 | 7 | P04908, Q93077, P62807, O60814, P68431, O43315, Q16539 | H2AC4; H2AC8, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | | | Cinnarizine | hsa04621 | NOD-like receptor signaling pathway | 3.40E-02 | 8 | Q14643, P10599, P43490, O00463, P29728, P01375, P09341, P12838 | ITPR1, TXN, PBEF1, TRAF5, OAS2, TNF, CXCL1, DEFA4 | More | | | Cinnarizine | hsa04622 | RIG-I-like receptor signaling pathway | 2.47E-02 | 1 | Q12933 | TRAF2 | More | | | Cinnarizine | hsa04623 | Cytosolic DNA-sensing pathway | 3.15E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | | | Cinnarizine | hsa04640 | Hematopoietic cell lineage | 2.00E-07 | 13 | P13612, P21926, P14778, P27930, P11215, P25063, P07766, P09693, P01732, P01730, P09564, P13765, P01375 | ITGA4, CD9, IL1R1, IL1R2, ITGAM, CD24, CD3E, CD3G, CD8A, CD4, CD7, HLA-DOB, TNF | More | | | Cinnarizine | hsa04650 | Natural killer cell mediated cytotoxicity | 2.42E-11 | 15 | P19174, P01375, P78314, P06239, O60880, P20963, P42338, Q13241, P26718, O14931, O75015, P26717, Q07444, Q14953, P26715 | PLCG1, TNF, SH3BP2, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KLRC3, KIR2DS5, KLRC1 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P24723 | PRKCH | Protein kinase C eta type | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.767 | | Q04759 | PRKCQ | Protein kinase C theta type | P01375 | TNF | Tumor necrosis factor | -0.725 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.718 | | Q04759 | PRKCQ | Protein kinase C theta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.779 | | P24723 | PRKCH | Protein kinase C eta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.912 | | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P06239 | LCK | Tyrosine-protein kinase Lck | -0.709 | | Q04759 | PRKCQ | Protein kinase C theta type | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.855 | | P24723 | PRKCH | Protein kinase C eta type | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.835 | | P06239 | LCK | Tyrosine-protein kinase Lck | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.906 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.764 | | Q04759 | PRKCQ | Protein kinase C theta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.92 | | P24723 | PRKCH | Protein kinase C eta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.939 | | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.703 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.727 | | P24723 | PRKCH | Protein kinase C eta type | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.79 | | Q04759 | PRKCQ | Protein kinase C theta type | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.849 | | P24723 | PRKCH | Protein kinase C eta type | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.768 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.758 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | | Q04759 | PRKCQ | Protein kinase C theta type | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.918 | | P24723 | PRKCH | Protein kinase C eta type | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.822 | | P06239 | LCK | Tyrosine-protein kinase Lck | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.886 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.803 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.701 | | P24723 | PRKCH | Protein kinase C eta type | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.828 | | P06239 | LCK | Tyrosine-protein kinase Lck | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.732 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.81 | | Q04759 | PRKCQ | Protein kinase C theta type | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.803 | | P06239 | LCK | Tyrosine-protein kinase Lck | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.756 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | | P24723 | PRKCH | Protein kinase C eta type | Q07444 | KLRC3 | NKG2-E type II integral membrane protein | 0.723 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | | Q04759 | PRKCQ | Protein kinase C theta type | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.803 | | P06239 | LCK | Tyrosine-protein kinase Lck | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.756 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 |
| | Cinnarizine | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | | | Cinnarizine | hsa04658 | Th1 and Th2 cell differentiation | 4.00E-16 | 14 | Q04759, P07766, P20963, P09693, Q16539, P19174, P01730, P06239, Q14765, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, PLCG1, CD4, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| Q04759 | PRKCQ | Protein kinase C theta type | Q04759 | PRKCQ | Protein kinase C theta type | 1 | | P24723 | PRKCH | Protein kinase C eta type | Q04759 | PRKCQ | Protein kinase C theta type | 0.791 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | | Q04759 | PRKCQ | Protein kinase C theta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.713 | | P24723 | PRKCH | Protein kinase C eta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.887 | | P07948 | LYN | Tyrosine-protein kinase Lyn | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.824 | | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | | Q04759 | PRKCQ | Protein kinase C theta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.92 | | P24723 | PRKCH | Protein kinase C eta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.939 | | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.703 | | Q04759 | PRKCQ | Protein kinase C theta type | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.756 | | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.734 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.901 | | P24723 | PRKCH | Protein kinase C eta type | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.767 | | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | | Q04759 | PRKCQ | Protein kinase C theta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.779 | | P24723 | PRKCH | Protein kinase C eta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.912 | | P07948 | LYN | Tyrosine-protein kinase Lyn | P06239 | LCK | Tyrosine-protein kinase Lck | -0.701 | | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P06239 | LCK | Tyrosine-protein kinase Lck | -0.709 | | Q04759 | PRKCQ | Protein kinase C theta type | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | 0.746 | | Q04759 | PRKCQ | Protein kinase C theta type | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.867 | | P06239 | LCK | Tyrosine-protein kinase Lck | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.77 | | Q04759 | PRKCQ | Protein kinase C theta type | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.843 | | P24723 | PRKCH | Protein kinase C eta type | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.856 | | P07948 | LYN | Tyrosine-protein kinase Lyn | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.719 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.866 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.73 | | P24723 | PRKCH | Protein kinase C eta type | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.876 | | P07948 | LYN | Tyrosine-protein kinase Lyn | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.771 | | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | | Q04759 | PRKCQ | Protein kinase C theta type | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.82 | | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.731 | | P24723 | PRKCH | Protein kinase C eta type | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.915 | | P07948 | LYN | Tyrosine-protein kinase Lyn | Q13761 | RUNX3 | Runt-related transcription factor 3 | -0.855 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.85 |
| | Cinnarizine | hsa04659 | Th17 cell differentiation | 3.39E-16 | 17 | Q04759, Q16539, P19174, P01730, P06239, P14784, P13765, P14778, Q9HBE5, Q9UL17, P23771, P84022, Q13485, P08238, P07766, P09693, P20963 | PRKCQ, MAPK14, PLCG1, CD4, LCK, IL2RB, HLA-DOB, IL1R1, IL21R, TBX21, GATA3, SMAD3, SMAD4, HSP90AB1, CD3E, CD3G, CD247 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| Q04759 | PRKCQ | Protein kinase C theta type | Q04759 | PRKCQ | Protein kinase C theta type | 1 | | P24723 | PRKCH | Protein kinase C eta type | Q04759 | PRKCQ | Protein kinase C theta type | 0.791 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.901 | | P24723 | PRKCH | Protein kinase C eta type | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.767 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | | Q04759 | PRKCQ | Protein kinase C theta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.779 | | P24723 | PRKCH | Protein kinase C eta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.912 | | P07948 | LYN | Tyrosine-protein kinase Lyn | P06239 | LCK | Tyrosine-protein kinase Lck | -0.701 | | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P06239 | LCK | Tyrosine-protein kinase Lck | -0.709 | | P24723 | PRKCH | Protein kinase C eta type | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.876 | | P07948 | LYN | Tyrosine-protein kinase Lyn | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.771 | | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 | | Q04759 | PRKCQ | Protein kinase C theta type | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.82 | | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.731 | | P24723 | PRKCH | Protein kinase C eta type | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.705 | | P07948 | LYN | Tyrosine-protein kinase Lyn | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.714 | | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.909 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.764 | | Q04759 | PRKCQ | Protein kinase C theta type | Q9HBE5 | IL21R | Interleukin-21 receptor | 0.8 | | P24723 | PRKCH | Protein kinase C eta type | Q9HBE5 | IL21R | Interleukin-21 receptor | 0.776 | | Q04759 | PRKCQ | Protein kinase C theta type | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.843 | | P24723 | PRKCH | Protein kinase C eta type | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.856 | | P07948 | LYN | Tyrosine-protein kinase Lyn | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.719 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.866 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.73 | | Q04759 | PRKCQ | Protein kinase C theta type | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.867 | | P06239 | LCK | Tyrosine-protein kinase Lck | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.77 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | | P07948 | LYN | Tyrosine-protein kinase Lyn | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.729 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | | P07948 | LYN | Tyrosine-protein kinase Lyn | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.782 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | | Q04759 | PRKCQ | Protein kinase C theta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.713 | | P24723 | PRKCH | Protein kinase C eta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.887 | | P07948 | LYN | Tyrosine-protein kinase Lyn | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.824 | | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.838 | | Q04759 | PRKCQ | Protein kinase C theta type | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.756 | | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.734 | | Q04759 | PRKCQ | Protein kinase C theta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.92 | | P24723 | PRKCH | Protein kinase C eta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.939 | | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.703 |
| | Cinnarizine | hsa04660 | T cell receptor signaling pathway | 3.15E-09 | 13 | P01375, Q04759, P42338, O95267, Q08881, P19174, P07766, P20963, P09693, P01730, P01732, Q13191, P06239 | TNF, PRKCQ, PIK3CB, RASGRP1, ITK, PLCG1, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| Q04759 | PRKCQ | Protein kinase C theta type | P01375 | TNF | Tumor necrosis factor | -0.725 | | Q04759 | PRKCQ | Protein kinase C theta type | Q04759 | PRKCQ | Protein kinase C theta type | 1 | | P24723 | PRKCH | Protein kinase C eta type | Q04759 | PRKCQ | Protein kinase C theta type | 0.791 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | | P24723 | PRKCH | Protein kinase C eta type | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.79 | | Q04759 | PRKCQ | Protein kinase C theta type | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | 0.733 | | Q04759 | PRKCQ | Protein kinase C theta type | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.803 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.774 | | P24723 | PRKCH | Protein kinase C eta type | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.767 | | Q04759 | PRKCQ | Protein kinase C theta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.713 | | P24723 | PRKCH | Protein kinase C eta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.887 | | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | | Q04759 | PRKCQ | Protein kinase C theta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.92 | | P24723 | PRKCH | Protein kinase C eta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.939 | | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | | Q04759 | PRKCQ | Protein kinase C theta type | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.756 | | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | | Q04759 | PRKCQ | Protein kinase C theta type | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.861 | | P24723 | PRKCH | Protein kinase C eta type | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.838 | | P06239 | LCK | Tyrosine-protein kinase Lck | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.841 | | Q04759 | PRKCQ | Protein kinase C theta type | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.767 | | P24723 | PRKCH | Protein kinase C eta type | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.779 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.714 | | Q04759 | PRKCQ | Protein kinase C theta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.779 | | P24723 | PRKCH | Protein kinase C eta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.912 | | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 |
| | Cinnarizine | hsa04662 | B cell receptor signaling pathway | 1.16E-04 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | | Cinnarizine | hsa04664 | Fc epsilon RI signaling pathway | 2.47E-02 | 4 | P42338, P07948, P19174, P09917 | PIK3CB, LYN, PLCG1, ALOX5 | More | | | Cinnarizine | hsa04668 | TNF signaling pathway | 2.67E-03 | 6 | P01375, P18848, P19875, P01584, P14780, P20333 | TNF, ATF4, CXCL2, IL1B, MMP9, TNFRSF1B | More | | | Cinnarizine | hsa04672 | Intestinal immune network for IgA production | 1.35E-02 | 2 | P29965, P13765 | CD40LG, HLA-DOB | More | | | Cinnarizine | hsa04710 | Circadian rhythm | 3.74E-03 | 2 | O00327, O15055 | ARNTL, PER2 | More | | | Cinnarizine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | | Cinnarizine | hsa04721 | Synaptic vesicle cycle | 3.15E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | | | Cinnarizine | hsa04722 | Neurotrophin signaling pathway | 1.98E-03 | 5 | Q05655, P49841, O43524, P48023, P52566 | PRKCD, GSK3B, FOXO3, FASLG, ARHGDIB | More | | | Cinnarizine | hsa04724 | Glutamatergic synapse | 2.22E-02 | 4 | O15399, P63218, P50151, P15104 | GRIN2D, GNG5, GNG10, GLUL | More | | | Cinnarizine | hsa04727 | GABAergic synapse | 4.42E-02 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | | | Cinnarizine | hsa04730 | Long-term depression | 1.55E-03 | 2 | Q14344, P08069 | GNA13, IGF1R | More | | | Cinnarizine | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | | | Cinnarizine | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | | Cinnarizine | hsa04750 | Inflammatory mediator regulation of TRP channels | 2.19E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | | Cinnarizine | hsa04913 | Ovarian steroidogenesis | 7.72E-03 | 3 | P42330, P22694, P08069 | AKR1C3, PRKACB, IGF1R | More | | | Cinnarizine | hsa04914 | Progesterone-mediated oocyte maturation | 2.16E-02 | 1 | P08069 | IGF1R | More | | | Cinnarizine | hsa04918 | Thyroid hormone synthesis | 3.16E-02 | 2 | P17252, P27824 | PRKCA, CANX | More | | | Cinnarizine | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | | | Cinnarizine | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | | Cinnarizine | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | | Cinnarizine | hsa04930 | Type II diabetes mellitus | 9.83E-04 | 2 | Q05655, Q02156 | PRKCD, PRKCE | More | | | Cinnarizine | hsa04932 | Non-alcoholic fatty liver disease | 1.52E-05 | 10 | P01375, P49841, O43521, P18848, P48023, O75460, P01584, P13073, Q16718, O14521 | TNF, GSK3B, BCL2L11, ATF4, FASLG, ERN1, IL1B, COX4I1, NDUFA5, SDHD | More | | | Cinnarizine | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.21E-02 | 5 | P84022, Q13485, P42338, P49767, P19174 | SMAD3, SMAD4, PIK3CB, VEGFC, PLCG1 | More | | | Cinnarizine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Cinnarizine | hsa04960 | Aldosterone-regulated sodium reabsorption | 4.38E-02 | 1 | P48048 | KCNJ1 | More | | | Cinnarizine | hsa04962 | Vasopressin-regulated water reabsorption | 1.80E-02 | 2 | P62491, P46459 | RAB11A, NSF | More | | | Cinnarizine | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | | | Cinnarizine | hsa04974 | Protein digestion and absorption | 2.47E-02 | 1 | Q7Z2H8 | SLC36A1 | More | | | Cinnarizine | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | | Cinnarizine | hsa05010 | Alzheimer disease | 2.78E-02 | 6 | P13073, O75460, P0DP24, P01584, P18848, P05141 | COX4I1, ERN1, CALM2, IL1B, ATF4, SLC25A5 | More | | | Cinnarizine | hsa05012 | Parkinson disease | 3.89E-02 | 5 | P13073, P05141, O75460, P18848, P0DP24 | COX4I1, SLC25A5, ERN1, ATF4, CALM2 | More | | | Cinnarizine | hsa05016 | Huntington disease | 1.05E-04 | 8 | P13073, Q9GZM3, P24928, P62487, P52435, P05141, Q9NYC9, O75460 | COX4I1, POLR2J2, POLR2A, POLR2G, POLR2J, SLC25A5, DNAH9, ERN1 | More | | | Cinnarizine | hsa05017 | Spinocerebellar ataxia | 2.22E-02 | 4 | Q92915, O15399, P42338, P21796 | FGF14, GRIN2D, PIK3CB, VDAC1 | More | | | Cinnarizine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | | | Cinnarizine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 6.94E-04 | 13 | P49841, Q16718, O14521, P13073, O75460, P18848, Q13561, P05141, P20333, Q16539, P01584, Q08752, P0DP24 | GSK3B, NDUFA5, SDHD, COX4I1, ERN1, ATF4, DCTN2, SLC25A5, TNFRSF1B, MAPK14, IL1B, PPID, CALM2 | More | | | Cinnarizine | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | | Cinnarizine | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | | Cinnarizine | hsa05100 | Bacterial invasion of epithelial cells | 4.50E-02 | 1 | Q92529 | SHC3 | More | | | Cinnarizine | hsa05110 | Vibrio cholerae infection | 4.78E-02 | 1 | Q99437 | ATP6V0B | More | | | Cinnarizine | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 4.95E-02 | 3 | P09341, P19875, P19174 | CXCL1, CXCL2, PLCG1 | More | | | Cinnarizine | hsa05131 | Shigellosis | 8.54E-04 | 4 | Q12933, Q05655, Q02156, P07737 | TRAF2, PRKCD, PRKCE, PFN1 | More | | | Cinnarizine | hsa05132 | Salmonella infection | 4.88E-02 | 2 | P84095, P07737 | RHOG, PFN1 | More | | | Cinnarizine | hsa05134 | Legionellosis | 4.88E-03 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | | Cinnarizine | hsa05135 | Yersinia infection | 4.39E-02 | 4 | P06239, P19174, P42338, P01732 | LCK, PLCG1, PIK3CB, CD8A | More | | | Cinnarizine | hsa05140 | Leishmaniasis | 1.56E-02 | 5 | P14598, P42224, P25963, P29350, Q15080 | NCF1, STAT1, NFKBIA, PTPN6, NCF4 | More | | | Cinnarizine | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | | Cinnarizine | hsa05144 | Malaria | 7.09E-04 | 5 | P60033, O60603, P01375, P35443, P26718 | CD81, TLR2, TNF, THBS4, KLRK1 | More | | | Cinnarizine | hsa05146 | Amoebiasis | 2.76E-09 | 12 | P09341, P19875, P14778, P27930, P01375, P42338, P11215, P05089, P30679, P22694, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, PIK3CB, ITGAM, ARG1, GNA15, PRKACB, ACTN1, CTSG | More | | | Cinnarizine | hsa05152 | Tuberculosis | 4.16E-02 | 2 | Q99437, P25774 | ATP6V0B, CTSS | More | | | Cinnarizine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | | Cinnarizine | hsa05168 | Herpes simplex virus 1 infection | 3.38E-03 | 12 | P25963, P01568, Q05823, P42224, Q07955, Q13243, Q13489, Q13398, Q9HCX3, P52738, O75820, Q9UDV6 | NFKBIA, IFNA21, RNASEL, STAT1, SFRS1, SFRS5, BIRC3, ZNF211, ZNF304, ZNF140, ZNF189, ZNF212 | More | | | Cinnarizine | hsa05169 | Epstein-Barr virus infection | 8.84E-05 | 14 | P13765, P01106, Q13547, O00463, Q16539, P07948, Q13761, P24522, P01375, O60603, P29728, P07766, P09693, P20963 | HLA-DOB, MYC, HDAC1, TRAF5, MAPK14, LYN, RUNX3, GADD45A, TNF, TLR2, OAS2, CD3E, CD3G, CD247 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| Q04759 | PRKCQ | Protein kinase C theta type | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.82 | | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.731 | | P06239 | LCK | Tyrosine-protein kinase Lck | P01106 | MYC | Myc proto-oncogene protein | 0.719 | | Q04759 | PRKCQ | Protein kinase C theta type | Q13547 | HDAC1 | Histone deacetylase 1 | 0.723 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q13547 | HDAC1 | Histone deacetylase 1 | 0.811 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q13547 | HDAC1 | Histone deacetylase 1 | -0.727 | | Q04759 | PRKCQ | Protein kinase C theta type | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.81 | | P06239 | LCK | Tyrosine-protein kinase Lck | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.718 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.788 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.901 | | P06239 | LCK | Tyrosine-protein kinase Lck | P07948 | LYN | Tyrosine-protein kinase Lyn | -0.701 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.85 | | Q04759 | PRKCQ | Protein kinase C theta type | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.846 | | P06239 | LCK | Tyrosine-protein kinase Lck | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.724 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.796 | | Q04759 | PRKCQ | Protein kinase C theta type | P01375 | TNF | Tumor necrosis factor | -0.725 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | O60603 | TLR2 | Toll-like receptor 2 | 0.72 | | Q04759 | PRKCQ | Protein kinase C theta type | P29728 | OAS2 | 2'-5'-oligoadenylate synthase 2 | 0.875 | | Q04759 | PRKCQ | Protein kinase C theta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.713 | | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | | Q04759 | PRKCQ | Protein kinase C theta type | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.756 | | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.734 | | Q04759 | PRKCQ | Protein kinase C theta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.92 | | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.703 |
| | Cinnarizine | hsa05200 | Pathways in cancer | 9.46E-03 | 17 | Q13751, P42338, P08238, P19174, P43246, P84022, Q13485, Q13547, P30281, P49767, P43657, P63218, P50151, Q14344, Q7LDG7, O75293, P14784 | LAMB3, PIK3CB, HSP90AB1, PLCG1, MSH2, SMAD3, SMAD4, HDAC1, CCND3, VEGFC, P2RY5, GNG5, GNG10, GNA13, RASGRP2, GADD45B, IL2RB | More | | | Cinnarizine | hsa05202 | Transcriptional misregulation in cancer | 3.47E-03 | 11 | P14780, P27930, Q15744, Q16548, P08069, P05164, P12838, P08246, Q9C0K0, Q13547, P24522 | MMP9, IL1R2, CEBPE, BCL2A1, IGF1R, MPO, DEFA4, ELA2, BCL11B, HDAC1, GADD45A | More | | | Cinnarizine | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | | Cinnarizine | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | | Cinnarizine | hsa05205 | Proteoglycans in cancer | 1.38E-03 | 10 | Q12955, Q14247, P14780, P17252, P01375, P08069, P23588, Q13635, P22694, P08962 | ANK3, CTTN, MMP9, PRKCA, TNF, IGF1R, EIF4B, PTCH1, PRKACB, CD63 | More | | | Cinnarizine | hsa05212 | Pancreatic cancer | 3.94E-02 | 4 | P42338, P84022, Q13485, O75293 | PIK3CB, SMAD3, SMAD4, GADD45B | More | | | Cinnarizine | hsa05214 | Glioma | 9.95E-03 | 1 | P08069 | IGF1R | More | | | Cinnarizine | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P08069 | IGF1R | More | | | Cinnarizine | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | | | Cinnarizine | hsa05218 | Melanoma | 6.63E-03 | 1 | P08069 | IGF1R | More | | | Cinnarizine | hsa05220 | Chronic myeloid leukemia | 2.16E-02 | 5 | Q13547, Q13485, P84022, P42338, O75293 | HDAC1, SMAD4, SMAD3, PIK3CB, GADD45B | More | | | Cinnarizine | hsa05221 | Acute myeloid leukemia | 4.95E-02 | 3 | P42338, Q15744, P11215 | PIK3CB, CEBPE, ITGAM | More | | | Cinnarizine | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | | | Cinnarizine | hsa05224 | Breast cancer | 1.49E-02 | 1 | P08069 | IGF1R | More | | | Cinnarizine | hsa05225 | Hepatocellular carcinoma | 6.30E-04 | 3 | Q92529, P08069, P51531 | SHC3, IGF1R, SMARCA2 | More | | | Cinnarizine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 3.09E-08 | 12 | P42338, O95267, P19174, P07766, P20963, P09693, P06239, O60603, Q04759, Q16539, Q9HC35, P01730 | PIK3CB, RASGRP1, PLCG1, CD3E, CD247, CD3G, LCK, TLR2, PRKCQ, MAPK14, EML4, CD4 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P24723 | PRKCH | Protein kinase C eta type | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.79 | | Q04759 | PRKCQ | Protein kinase C theta type | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | 0.733 | | P24723 | PRKCH | Protein kinase C eta type | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.767 | | Q04759 | PRKCQ | Protein kinase C theta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.713 | | P24723 | PRKCH | Protein kinase C eta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.887 | | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | | P52732 | KIF11 | Kinesin-like protein KIF11 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.724 | | Q04759 | PRKCQ | Protein kinase C theta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.92 | | P24723 | PRKCH | Protein kinase C eta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.939 | | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.703 | | Q04759 | PRKCQ | Protein kinase C theta type | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.756 | | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.734 | | Q04759 | PRKCQ | Protein kinase C theta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.779 | | P24723 | PRKCH | Protein kinase C eta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.912 | | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | | P52732 | KIF11 | Kinesin-like protein KIF11 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.721 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P06239 | LCK | Tyrosine-protein kinase Lck | -0.709 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | O60603 | TLR2 | Toll-like receptor 2 | 0.72 | | Q04759 | PRKCQ | Protein kinase C theta type | Q04759 | PRKCQ | Protein kinase C theta type | 1 | | P24723 | PRKCH | Protein kinase C eta type | Q04759 | PRKCQ | Protein kinase C theta type | 0.791 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.901 | | P52732 | KIF11 | Kinesin-like protein KIF11 | Q9HC35 | EML4 | Echinoderm microtubule-associated protein-like 4 | 0.794 | | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | | P52732 | KIF11 | Kinesin-like protein KIF11 | P01730 | CD4 | T-cell surface glycoprotein CD4 | -0.719 |
| | Cinnarizine | hsa05310 | Asthma | 2.59E-04 | 4 | P13765, P29965, P12724, P01375 | HLA-DOB, CD40LG, RNASE3, TNF | More | | | Cinnarizine | hsa05320 | Autoimmune thyroid disease | 3.16E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | | | Cinnarizine | hsa05321 | Inflammatory bowel disease | 1.83E-05 | 6 | P01375, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TNF, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | | | Cinnarizine | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | | Cinnarizine | hsa05323 | Rheumatoid arthritis | 4.95E-02 | 3 | Q06643, P09341, P19875 | LTB, CXCL1, CXCL2 | More | | | Cinnarizine | hsa05330 | Allograft rejection | 1.76E-03 | 4 | P13765, P29965, P48023, P01375 | HLA-DOB, CD40LG, FASLG, TNF | More | | | Cinnarizine | hsa05332 | Graft-versus-host disease | 2.11E-06 | 5 | P13765, P48023, P01375, P26715, Q13241 | HLA-DOB, FASLG, TNF, KLRC1, KLRD1 | More | | | Cinnarizine | hsa05340 | Primary immunodeficiency | 2.02E-05 | 5 | P01730, P01732, P11912, P07766, P06239 | CD4, CD8A, CD79A, CD3E, LCK | More | | | Cinnarizine | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 1.82E-02 | 3 | P14923, P08514, Q9UJU2 | JUP, ITGA2B, LEF1 | More | | | Cinnarizine | hsa05415 | Diabetic cardiomyopathy | 4.54E-04 | 8 | P17252, P14598, Q15080, Q16718, O14521, Q16539, P49841, P04406 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, MAPK14, GSK3B, GAPDH | More | | | Cinnarizine | hsa05416 | Viral myocarditis | 4.29E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | |
|
